2010
Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines
Hernandez-Ilizaliturri F, Mavis C, Maraj I, Chisti M, Gibbs J, Czuczman M. Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines. Blood 2010, 116: 3936. DOI: 10.1182/blood.v116.21.3936.3936.Peer-Reviewed Original ResearchCell linesBcl-xLBcl-2 family proteinsBcl-2 family membersLymphoma cell linesProteasome inhibitorsRegulation of BakAnti-tumor activityLymphoma cellsB-cell lymphomaCellular processesFamily proteinsWestern blotGene transcriptionPan-caspaseHistone deacetylase inhibitorsSingle agentTarget proteinsCaspase inhibitionMolecular eventsAlamar Blue reductionMcl-1Mitochondrial potentialATP synthesisHodgkin's lymphoma cell lines
2009
Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal Of Clinical Oncology 2009, 27: 8576-8576. DOI: 10.1200/jco.2009.27.15_suppl.8576.Peer-Reviewed Original ResearchRituximab-sensitive cell linesRituximab-resistant cell linesCell linesB-cell lymphomaBcl-2 family membersPatient-derived tumor cellsChemotherapy agentsNHL cell linesMonoclonal antibodiesPatient-derived tumour cellsBcl-xL geneCellular processesTumor cellsEffects of LBH589Polymerase chain reactionGene transcriptionGene expressionTarget proteinsAlamar Blue reductionMitochondrial potentialAntitumor activityNegative selectionSequence of administrationQualitative polymerase chain reactionCell titer